semaglutide

News

Semaglutide heart benefits may go beyond weight loss

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss.

News

Semaglutide scores again, this time in heart failure

The list of benefits for Novo Nordisk's semaglutide keeps getting longer.

News

Novo Nordisk, Lilly highlight oral obesity drugs at ADA

New data from Novo Nordisk’s phase 3 trial of an oral, high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli Lilly is

News

Novo Nordisk says oral Wegovy hits weight loss goal

Novo Nordisk has struck back in its growing rivalry with Eli Lilly in the obesity market, with data showing a higher-dose version of its oral version of weight loss drug W

News

FDA ends 7-year obesity drug drought, clearing Novo Nordisk'...

Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which it believes has the potential to redefine the market for weight-loss medicine

News